E Wallerstedt1, U Smith, C X Andersson. 1. The Lundberg Laboratory for Diabetes Research, Center of Excellence for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine/Diabetes, The Sahlgrenska Academy at University of Gothenburg, Blå Stråket 5, SE-413 45, Gothenburg, Sweden.
Abstract
AIMS/HYPOTHESIS: The aim of the study was to address the role of protein kinase C-delta (PKCdelta) on phosphorylation of signal transducer and activator of transcription 3 (STAT3) and activation of inflammatory genes in response to IL-6 in adipose cells. METHODS: Differentiated mouse 3T3-L1 adipocytes preincubated with the PKCdelta inhibitor rottlerin and mouse embryonic fibroblasts (MEFs) lacking PKCdelta were incubated with IL-6 and/or insulin. RNA was extracted and the gene expression was analysed by real-time PCR, while the proteins from total, nuclear and cytoplasmic lysates were analysed by immunoblotting. RESULTS: Inhibition of PKCdelta by rottlerin significantly reduced both Ser-727 and Tyr-705 phosphorylation of STAT3. Consequently, nuclear translocation of STAT3 and the IL-6-induced gene transcription and protein release of the inflammatory molecule serum amyloid A 3 (SAA3) were reduced. Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin. Furthermore, PKCdelta was found to translocate to the nucleus following IL-6 treatment and this was also reduced by rottlerin. In agreement with the effect of rottlerin, Pkcdelta (also known as Prkcd) ( -/- ) MEFs also displayed a markedly reduced ability of IL-6 to activate the transcription of Saa3, Hp, Socs3 and Il6 genes compared with wild-type MEFs. These results correlated with a reduced nuclear translocation and phosphorylation of STAT3. CONCLUSIONS/ INTERPRETATION: These results show that PKCdelta plays a key role in the inflammatory effect of IL-6 in adipose cells and may be a suitable target for novel anti-inflammatory agents.
AIMS/HYPOTHESIS: The aim of the study was to address the role of protein kinase C-delta (PKCdelta) on phosphorylation of signal transducer and activator of transcription 3 (STAT3) and activation of inflammatory genes in response to IL-6 in adipose cells. METHODS: Differentiated mouse 3T3-L1 adipocytes preincubated with the PKCdelta inhibitor rottlerin and mouse embryonic fibroblasts (MEFs) lacking PKCdelta were incubated with IL-6 and/or insulin. RNA was extracted and the gene expression was analysed by real-time PCR, while the proteins from total, nuclear and cytoplasmic lysates were analysed by immunoblotting. RESULTS: Inhibition of PKCdelta by rottlerin significantly reduced both Ser-727 and Tyr-705 phosphorylation of STAT3. Consequently, nuclear translocation of STAT3 and the IL-6-induced gene transcription and protein release of the inflammatory molecule serum amyloid A 3 (SAA3) were reduced. Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin. Furthermore, PKCdelta was found to translocate to the nucleus following IL-6 treatment and this was also reduced by rottlerin. In agreement with the effect of rottlerin, Pkcdelta (also known as Prkcd) ( -/- ) MEFs also displayed a markedly reduced ability of IL-6 to activate the transcription of Saa3, Hp, Socs3 and Il6 genes compared with wild-type MEFs. These results correlated with a reduced nuclear translocation and phosphorylation of STAT3. CONCLUSIONS/ INTERPRETATION: These results show that PKCdelta plays a key role in the inflammatory effect of IL-6 in adipose cells and may be a suitable target for novel anti-inflammatory agents.
Authors: Birgit Gustafson; Ann Hammarstedt; Christian X Andersson; Ulf Smith Journal: Arterioscler Thromb Vasc Biol Date: 2007-09-06 Impact factor: 8.311
Authors: V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack Journal: J Clin Endocrinol Metab Date: 1997-12 Impact factor: 5.958
Authors: S Franckhauser; I Elias; V Rotter Sopasakis; T Ferré; I Nagaev; C X Andersson; J Agudo; J Ruberte; F Bosch; U Smith Journal: Diabetologia Date: 2008-04-24 Impact factor: 10.122
Authors: Olivier Bezy; Thien T Tran; Jussi Pihlajamäki; Ryo Suzuki; Brice Emanuelli; Jonathan Winnay; Marcelo A Mori; Joel Haas; Sudha B Biddinger; Michael Leitges; Allison B Goldfine; Mary Elizabeth Patti; George L King; C Ronald Kahn Journal: J Clin Invest Date: 2011-05-16 Impact factor: 14.808
Authors: Sarah M Brotman; Chelsea K Raulerson; Swarooparani Vadlamudi; Kevin W Currin; Qiujin Shen; Victoria A Parsons; Apoorva K Iyengar; Tamara S Roman; Terrence S Furey; Johanna Kuusisto; Francis S Collins; Michael Boehnke; Markku Laakso; Päivi Pajukanta; Karen L Mohlke Journal: Am J Hum Genet Date: 2022-01-06 Impact factor: 11.043
Authors: Carrie E McCurdy; Simon Schenk; Michael J Holliday; Andrew Philp; Julie A Houck; David Patsouris; Paul S MacLean; Susan M Majka; Dwight J Klemm; Jacob E Friedman Journal: Diabetes Date: 2012-06-14 Impact factor: 9.461
Authors: Lisette J A Kogelman; Jingyuan Fu; Lude Franke; Jan Willem Greve; Marten Hofker; Sander S Rensen; Haja N Kadarmideen Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240